Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAGCHE)

• Drug Name: Multi-envelope HIV vaccine Drug Info
• Synonyms: PolyEnv1; AIDS vaccine, St Jude; HIV vaccine, St Jude; Multi-envelope AIDS vaccine, St Jude; Multi-envelope HIV vaccine, St Jude; Vaccine (HIV), St Jude

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMAGCHE

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fostemsavir	DM50ILT	Human immunodeficiency virus infection	1C62	Approved	[3]
AIDSVAX	DMS2WV3	Human immunodeficiency virus infection	1C62	Phase 3	[4]
BMS-488043	DMRPU10	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[5]
Pro 542	DMLOGR3	Human immunodeficiency virus infection	1C62	Discontinued in Phase 2	[6]
PF-821385	DMNZG8T	Human immunodeficiency virus infection	1C62	Preclinical	[7]
CD4 red blood cell electroinsertion	DMIV82T	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Human immunodeficiency virus Glycoprotein 41 (HIV gp41)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enfuvirtide	DM7YPM1	Human immunodeficiency virus infection	1C62	Approved	[9]
Sifuvirtide	DMMIWCE	Human immunodeficiency virus infection	1C62	Phase 3	[10]
ITV-1	DMCJX79	Human immunodeficiency virus infection	1C62	Phase 2	[11]
T-1249	DMB2NP8	Human immunodeficiency virus infection	1C62	Phase 1/2	[12]
MaC46/M87o	DMIRG15	Human immunodeficiency virus-1 infection	1C62	Phase 1/2	[13]
Combinectin	DMTLP1N	Human immunodeficiency virus infection	1C62	Phase 1	[14]
Gp41 HIV-1 vaccine	DM9JV80	Human immunodeficiency virus infection	1C62	Phase 1	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120)	TTBYP1X	ENV_HV1H2	Not Available	[2]
Human immunodeficiency virus Glycoprotein 41 (HIV gp41)	TTG90S6	ENV_HV1H2	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT00187044) Evaluation of the Safety of a Polyvalent Virus in Healthy Adults. U.S. National Institutes of Health.
• [2] An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020
• [4] HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D. 2003;4(4):249-53.
• [5] The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations.J Mol Model.2013 Feb;19(2):905-17.
• [6] Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004 Feb;48(2):423-9.
• [7] Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution. PLoS Pathog. 2013 February; 9(2): e1003184.
• [8] Red blood cells bearing CD4 bind to gp120 covered plates and aggregate with cells expressing gp120. J Acquir Immune Defic Syndr. 1990;3(11):1041-5.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [10] Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96.
• [11] Clinical pipeline report, company report or official report of Immunotech Laboratories.
• [12] HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8.
• [13] DOI: 10.1038/mt.sj.6300124
• [14] Clinical pipeline report, company report or official report of ViiV Healthcare.
• [15] Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617.